2024: Emergent trends in pharma and biotech

For many in the life sciences, the year gone by has been marked by volatility across a range of metrics, as political and economic disruptions threaten to upend the standard operating model.

Developers and commercial teams have faced a rapidly shifting landscape defined by trends that, while emerging prior to 2024, have become particularly prominent over the past year.

As may be expected, the United States maintained its position as the leader in pharmaceutical innovation, contributing to nearly half of all drugs in development. However, China’s influence in global R&D has grown significantly, with expanding clinical trial activity and first-to-market launches.